Marc R Pelletier

8PUBLICATIONS
171CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 14, 2026
TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

|Jun 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Jun 09, 2025
Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.

Lang Ho Lee, Xin Xu, Thanos Mourikis

|Mar 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro

|Jul 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler

|Apr 11, 2023
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.

Rohan Diwanji, Neil A O'Brien, Jiyoung E Choi

Pageof 2

Frequent Collaborators

3 joint publications

Jincheng Wu

3 joint publications

Glenn Dranoff

3 joint publications

Angelo L Grauel

2 joint publications

Viviana Cremasco